Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 4, Issue 3
February 11 2020
Issue Cover

Table of Contents

EXCEPTIONAL CASE REPORTS

A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia
Clinical Trials & Observations
Max Jan,Daniel E. Grinshpun,Julian A. Villalba,Paola Dal Cin,David B. Sykes,A. John Iafrate,Benjamin L. Ebert,Gabriela S. Hobbs,Valentina Nardi
View Articletitled, A cryptic imatinib-sensitive <em>G3BP1-PDGFRB</em> rearrangement in a myeloid neoplasm with eosinophilia
Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx
Marcus A. Carden,Manila Gaddh,Abhinav Hoskote,Michael Brown,Virginia Merrill,Sean R. Stowell,Shanmuganathan Chandrakasan,Ana Antun,Ragini Kudchadkar,Sarah Kotanchiyev,David L. Jaye,Imre Bodó
View Articletitled, Rituximab leads to early elimination of circulating CD20<sup>+</sup> T and B lymphocytes in patients with iTTP despite ongoing TPEx
Supplemental data

STIMULUS REPORTS

Treatment-free remission in FIP1L1-PDGFRA–positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation
Clinical Trials & Observations
Georgia Metzgeroth,Juliana Schwaab,Nicole Naumann,Mohamad Jawhar,Torsten Haferlach,Alice Fabarius,Andreas Hochhaus,Wolf-Karsten Hofmann,Nicholas C. P. Cross,Andreas Reiter
View Articletitled, Treatment-free remission in <em>FIP1L1-PDGFRA</em>–positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation
Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia
Victoria M. Smith,Oliver Lomas,Donna Constantine,Lianne Palmer,Anna H. Schuh,David Bruce,Oksana Gonchar,Salvador Macip,Sandrine Jayne,Martin J. S. Dyer,Toby A. Eyre
View Articletitled, Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia
Supplemental data

SYSTEMATIC REVIEW

Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis
Clinical Trials & Observations
Rasha Khatib,Stephanie Ross,Sean Alexander Kennedy,Ivan D. Florez,Thomas L. Ortel,Robby Nieuwlaat,Ignacio Neumann,Daniel M. Witt,Sam Schulman,Veena Manja,Rebecca Beyth,Nathan P. Clark,Wojtek Wiercioch,Holger J. Schünemann,Yuqing Zhang
View Articletitled, Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
Clinical Trials & Observations
Rakesh Awasthi,Lida Pacaud,Edward Waldron,Constantine S. Tam,Ulrich Jäger,Peter Borchmann,Samantha Jaglowski,Stephen Ronan Foley,Koen van Besien,Nina D. Wagner-Johnston,Marie José Kersten,Stephen J. Schuster,Gilles Salles,Richard T. Maziarz,Özlem Anak,Christopher del Corral,Jufen Chu,Irina Gershgorin,Iulian Pruteanu-Malinici,Abhijit Chakraborty,Karen Thudium Mueller,Edmund K. Waller
View Articletitled, Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial
Clinical Trials & Observations
Jennifer M. Knight,J. Douglas Rizzo,Parameswaran Hari,Marcelo C. Pasquini,Karen E. Giles,Anita D’Souza,Brent R. Logan,Mehdi Hamadani,Saurabh Chhabra,Binod Dhakal,Nirav Shah,Deepika Sriram,Mary M. Horowitz,Steve W. Cole
View Articletitled, Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

WASP and Mst1 coregulate B-cell development and B-cell receptor signaling
Lu Huang,Xiaoyu Sun,Di Yang,Xin Dai,Panpan Jiang,Xiaoming Bai,Yongjie Zhang,Jinzhi Wang,Wenyan Li,Heather Miller,Wenxia Song,Bebhinn Treanor,Xiaodong Zhao,Chaohong Liu
View Articletitled, WASP and Mst1 coregulate B-cell development and B-cell receptor signaling
Supplemental data

LYMPHOID NEOPLASIA

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia
Clinical Trials & Observations
Nitin Jain,Wendy Stock,Amer Zeidan,Ehab Atallah,James McCloskey,Leonard Heffner,Benjamin Tomlinson,Bhavana Bhatnagar,Jay Feingold,David Ungar,Grace Chao,Xiaoyan Zhang,Yajuan Qin,Karin Havenith,Hagop Kantarjian,Matthew J. Wieduwilt
View Articletitled, Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia
Supplemental data
Organ responses with daratumumab therapy in previously treated AL amyloidosis
Clinical Trials & Observations
Alfred Chung,Gregory P. Kaufman,Surbhi Sidana,Erik Eckhert,Stanley L. Schrier,Richard A. Lafayette,Sally Arai,Ronald M. Witteles,Michaela Liedtke
View Articletitled, Organ responses with daratumumab therapy in previously treated AL amyloidosis

MYELOID NEOPLASIA

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
Clinical Trials & Observations
Guillermo Montalban-Bravo,Rashmi Kanagal-Shamanna,Christopher B. Benton,Caleb A. Class,Kelly S. Chien,Koji Sasaki,Kiran Naqvi,Yesid Alvarado,Tapan M. Kadia,Farhad Ravandi,Naval Daver,Koichi Takahashi,Elias Jabbour,Gautham Borthakur,Naveen Pemmaraju,Marina Konopleva,Kelly A. Soltysiak,Sherry R. Pierce,Carlos E. Bueso-Ramos,Keyur P. Patel,Hagop Kantarjian,Guillermo Garcia-Manero
View Articletitled, Genomic context and <em>TP53</em> allele frequency define clinical outcomes in <em>TP53</em>-mutated myelodysplastic syndromes
Supplemental data
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
Clinical Trials & Observations
Theodore C. Tarver,Jason E. Hill,Leena Rahmat,Alexander E. Perl,Erkut Bahceci,Kenichi Mori,Catherine C. Smith
View Articletitled, Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
Supplemental data
Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia
Clinical Trials & Observations
Onyee Chan,Chetasi Talati,Leidy Isenalumhe,Samantha Shams,Lisa Nodzon,Michael Fradley,Kendra Sweet,Javier Pinilla-Ibarz
View Articletitled, Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia
Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia
Clinical Trials & Observations
Shady Adnan Awad,Matti Kankainen,Teija Ojala,Perttu Koskenvesa,Samuli Eldfors,Bishwa Ghimire,Ashwini Kumar,Soili Kytölä,Mahmoud M. Kamel,Caroline A. Heckman,Kimmo Porkka,Satu Mustjoki
View Articletitled, Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia
Supplemental data
Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies
Melissa A. Fischer,Sharon Y. Friedlander,Maria P. Arrate,Hua Chang,Agnieszka E. Gorska,Londa D. Fuller,Haley E. Ramsey,Trinayan Kashyap,Christian Argueta,Sophie Debler,Michael Byrne,Matthew T. Villaume,Aaron C. Shaver,William Senapedis,Yosef Landesman,Erkan Baloglu,Sharon Shacham,Michael R. Savona
View Articletitled, Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies
Supplemental data

THROMBOSIS AND HEMOSTASIS

Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura
George Goshua,Amit Gokhale,Jeanne E. Hendrickson,Christopher Tormey,Alfred Ian Lee
View Articletitled, Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura
Supplemental data

COMMENTARY

Understanding sickle cell disease: impact of surveillance and gaps in knowledge
Mandip Kaur,Mary Brown,Ted W. Love,Alexis Thompson,Marsha Treadwell,Kim Smith-Whitley
View Articletitled, Understanding sickle cell disease: impact of surveillance and gaps in knowledge

ERRATA

Jagannath S, Abonour R, Durie BGM, et al. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Adv. 2018;2(13):1608-1615.
View Articletitled, Jagannath S, Abonour R, Durie BGM, et al. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. <em>Blood Adv.</em> 2018;2(13):1608-1615.
Verbij FC, Sorvillo N, Kaijen PHP, et al. The class I scavenger receptor CD163 promotes internalization of ADAMTS13 by macrophages. Blood Adv. 2017;1(5):293-305.
View Articletitled, Verbij FC, Sorvillo N, Kaijen PHP, et al. The class I scavenger receptor CD163 promotes internalization of ADAMTS13 by macrophages. <em>Blood Adv.</em> 2017;1(5):293-305.
All Issues

Advertisement

Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy
Phillips NS, Mulrooney DA, Williams AM, et al. Neurocognitive impairment associated with chronic morbidity in long-term survivors of Hodgkin Lymphoma. Blood Adv. 2023;7(23):7270-7278.
Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia
Race and ethnicity reporting and representation in hemophilia clinical trials

Advertisement

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement